Participants | Diagnosis reached? | Investigations (%) | ||||||||||||||||
Result | FBC | ZPP | U&E | LFT | Bone profile | TFT | Biotinidase | CK | Lead level | Plasma amino acids | Urine organic acids | Urine GAGs | Karyotype | Microarray | Fragile X | MRI brain | ||
All participants (n=699) | 166 (23.7%) | Number receiving test | 526/699 (75.2%) | 278/699 (39.8%) | 512/699 (73.2%) | 491/699 (70.2%) | 429/699 (61.4%) | 469/699 (67.1%) | 227/699 (32.5%) | 388/699 (55.5%) | 40/699 (5.7%) | 413/699 (59.1%) | 318/699 (45.4%) | 217/699 (31.0%) | 96/699 (13.7%) | 442/699 (63.2%) | 113/699 (16.2%) | 368/699 (52.6%) |
Normal | 444/526 (84.4%) | 205/278 (73.7%) | 477/512 (93.2%) | 434/491 (88.4%) | 412/429 (96.0%) | 431/469 (91.9%) | 216/227 (95.2%) | 340/388 (87.6%) | 40/40 (100%) | 392/413 (94.9%) | 286/318 (90.0%) | 200/217 (92.2%) | 94/96 (97.9%) | 342/442 (77.4%) | 112/113 (99.1%) | 208/368 (56.5%) | ||
Abnormal: non-diagnostic | 82/526 (15.6%) | 73/278 (26.3%) | 35/512 (6.8%) | 57/491 (11.6%) | 17/429 (4.0%) | 35/469 (7.5%) | 11/227 (4.8%) | 48/388 (12.4%) | 0/40 (0%) | 16/413 (3.9%) | 29/318 (9.1%) | 17/217 (7.8%) | 0/96 (0%) | 49/442 (11.1%) | 0/113 (0%) | 75/368 (20.4%) | ||
Abnormal: diagnostic | 0/526 (0%) | 0/278 (0%) | 0/512 (0%) | 0/491 (0%) | 0/429 (0%) | 3/469 (0.6%)* | 0/227 (0%) | 0/388 (0%) | 0/40 (0%) | 5/413 (1.2%)† | 3/318 (0.9%)‡ | 0/217 (0%) | 2/96 (2.1%) | 51/442 (11.5%) | 1/113 (0.9%) | 85/368 (23.1%) | ||
EDI without additional features (n=142) | 14 (9.9%) | Number receiving test | 99/142 (69.7%) | 66/142 (46.5%) | 91/142 (64.1%) | 87/142 (61.3%) | 79/142 (55.6%) | 91/142 (64.1%) | 44/142 (31.0%) | 80/142 (56.3%) | 5/142 (3.5%) | 75/142 (52.8%) | 53/142 (37.3%) | 38/142 (26.8%) | 9/142 (6.3%) | 79/142 (55.6%) | 24/142 (16.9%) | 30/142 (21.1%) |
Normal | 86/99 (86.9%) | 52/66 (78.8%) | 90/91 (98.9%) | 81/87 (93.1%) | 75/79 (94.9%) | 86/91 (94.5%) | 44/44 (100%) | 73/80 (91.3%) | 5/5 (100%) | 71/75 (94.7%) | 50/53 (94.3%) | 31/38 (81.6%) | 9/9 (100%) | 60/79 (75.9%) | 23/24 (95.8%) | 20/30 (66.7%) | ||
Abnormal: non-diagnostic | 13/99 (13.1%) | 14/66 (21.2%) | 1/91 (1.1%) | 6/87 (6.9%) | 4/79 (5.1%) | 5/91 (5.5%) | 0/44 (0%) | 7/80 (8.7%) | 0/5 (0%) | 4/75 (5.3%) | 3/53 (5.7%) | 7/38 (18.4%) | 0/9 (0%) | 10/79 (12.7%) | 0/24 (0%) | 6/30 (20.0%) | ||
Abnormal: diagnostic | 0/99 (0%) | 0/66 (0%) | 0/91 (0%) | 0/87 (0%) | 0/79 (0%) | 0/91 (0%) | 0/44 (0%) | 0/80 (0%) | 0/5 (0%) | 0/75 (0%) | 0/53 (0%) | 0/38 (0%) | 0/9 (0%) | 9/79 (11.4%) | 1/24 (4.2%) | 4/30 (13.3%) | ||
All participants with EDI and additional features (n=557) | 152 (27.3%) | Number receiving test | 427/557 (76.7%) | 212/557 (38.1%) | 421/557 (75.6%) | 404/557 (72.5%) | 350/557 (62.8%) | 378/557 (67.9%) | 183/557 (32.9%) | 308/557 (55.3%) | 35/557 (6.3%) | 338/557 (60.7%) | 265/557 (47.6%) | 179/557 (32.1%) | 86/557 (15.4%) | 363/557 (65.2%) | 89/557 (16.0%) | 338/557 (60.7%) |
Normal | 358/428 (83.6%) | 153/212 (72.2%) | 387/421 (91.9%) | 353/404 (87.4%) | 337/350 (96.3%) | 345/378 (91.3%) | 172/183 (94.0%) | 267/308 (86.7%) | 0/35 (0%) | 321/338 (94.9%) | 236/265 (89.1%) | 169/179 (94.4%) | 84/86 (97.7%) | 282/363 (77.7%) | 89/89 (0%) | 188/338 (55.6%) | ||
Abnormal: non-diagnostic | 69/428 (16.1%) | 59/212 (27.8%) | 34/421 (8.1%) | 51/404 (12.6%) | 13/350 (3.7%) | 30/378 (7.9%) | 11/183 (6.0%) | 41/308 (13.3%) | 35/35 (100%) | 12/338 (3.6%) | 26/265 (9.8%) | 10/179 (5.6%) | 0/86 (0%) | 39/363 (10.7%) | 0/89 (0%) | 69/338 (20.4%) | ||
Abnormal: diagnostic | 0/428 (0%) | 0/212 (0%) | 0/421 (0%) | 0/404 (0%) | 0/350 (0%) | 3/378 (0.8%) | 0/183 (0%) | 0/308 (0%) | 0/35 (0%) | 5/338 (1.5%) | 3/265 (1.1%) | 0/179 (0%) | 2/86 (2.3%) | 42/363 (11.6%) | 0/89 (0%) | 81/338 (24.0%) |
*Thyroid function: (a) boy presented at 1 year 10 months as a placid baby with EDI most obvious in motor skills and with hypotonia. Autoimmune hypothyroidism diagnosed and he improved with treatment although subsequently developed ASD; (b) ex-preterm (29 weeks) girl investigated at 4 years 7 months to a mother with learning difficulties, had general developmental impairment, especially in speech skills who improved on treatment but had attention and behavioural difficulties; (c) girl investigated at 5 years 6 months for EDI, nystagmus with a history of maternal illicit drug use in pregnancy—showed improvement on treatment, but not to normal abilities. Dual diagnosis is being investigated.
†Plasma amino acids: (a) boy investigated at 4 years 1 month with EDI and seizures whose brother had similar phenotype diagnosed with homocystinuria; (b) 4-month-old boy with EDI, microcephaly, hypertonia and poor visual function with low serum and CSF serine, diagnosed with serine deficiency; (c) girl investigated at 2 years 11 months with EDI, brittle hair, eczema and dysmorphia diagnosed with ethylmalonic aciduria; (d) boy investigated at 4 years 7 months with EDI and faltering growth diagnosed with lysinuric protein intolerance; (e) boy investigated at 10 months with EDI, visual impairment and hypotonia noted to have low serum and CSF serine, diagnosed as serine deficiency.
‡Urine organic acids: ex-premature girl investigated at 8 months for EDI, acquired microcephaly and faltering growth with raised lactate and glutamate, subsequently diagnosed with pyruvate dehydrogenase deficiency; see cases (c) and (d) in the plasma amino acid results.
ASD, Autistic spectrum disorder; CSF, cerebrospinal fluid; CK, creatine kinase; EDI, early developmental impairment; FBC, full blood count; GAG, glycosaminoglycans; LFT, liver function test; TFT, thyroid function test; U&E, urea and electrolytes; ZPP, zinc protoporphyrin;